175 related articles for article (PubMed ID: 28174352)
21. Adipokines, endothelial dysfunction and nutritional status in peritoneal dialysis patients.
Małgorzewicz S; Lichodziejewska-Niemierko M; Aleksandrowicz-Wrona E; Świetlik D; Rutkowski B; Łysiak-Szydłowska W
Scand J Urol Nephrol; 2010 Dec; 44(6):445-51. PubMed ID: 20624111
[TBL] [Abstract][Full Text] [Related]
22. Tumor necrosis factor α is a risk factor for infection in peritoneal dialysis patients.
Kang E; Kim S; Lee HJ; Park I; Kim H; Shin GT
Korean J Intern Med; 2016 Jul; 31(4):722-9. PubMed ID: 27000486
[TBL] [Abstract][Full Text] [Related]
23. Role of online hemodiafiltration in improvement of inflammatory status in pediatric patients with end-stage renal disease.
Morad AA; Bazaraa HM; Abdel Aziz RE; Abdel Halim DA; Shoman MG; Saleh ME
Iran J Kidney Dis; 2014 Nov; 8(6):481-5. PubMed ID: 25362224
[TBL] [Abstract][Full Text] [Related]
24. Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia.
Shakeri A; Tabibi H; Hedayati M
Hemodial Int; 2010 Oct; 14(4):498-504. PubMed ID: 20812958
[TBL] [Abstract][Full Text] [Related]
25. Novel inflammatory marker in dialysis patients: YKL-40.
Okyay GU; Er RE; Tekbudak MY; Paşaoğlu Ö; Inal S; Öneç K; Paşaoğlu H; Altok K; Derici Ü; Erten Y
Ther Apher Dial; 2013 Apr; 17(2):193-201. PubMed ID: 23551676
[TBL] [Abstract][Full Text] [Related]
26. Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients.
Afzali B; Bakri RS; Bharma-Ariza P; Lumb PJ; Dalton N; Turner NC; Wierzbicki AS; Crook MA; Goldsmith DJ
J Nephrol; 2003; 16(4):540-5. PubMed ID: 14696756
[TBL] [Abstract][Full Text] [Related]
27. [Inflammatory status in patients with end-stage renal disease: role of monocyte activation].
Liang M; Wang L; Hou FF; Liu J; Liu ZQ; Tian JW
Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):781-4. PubMed ID: 12919896
[TBL] [Abstract][Full Text] [Related]
28. Inflammation and overweight in peritoneal dialysis: is there an association?
de Araujo Antunes A; Vannini FD; Martin LC; Balbi AL; Ponce D; Nunes HR; Barretti P; Caramori JC
Ren Fail; 2009; 31(7):549-54. PubMed ID: 19839849
[TBL] [Abstract][Full Text] [Related]
29. Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels.
Preston GA; Barrett CV; Alcorta DA; Hogan SL; Dinwiddie L; Jennette JC; Falk RJ
Nephron; 2002 Dec; 92(4):817-23. PubMed ID: 12399626
[TBL] [Abstract][Full Text] [Related]
30. Inflammation and Peritoneal Dialysis.
Li PK; Ng JK; Mcintyre CW
Semin Nephrol; 2017 Jan; 37(1):54-65. PubMed ID: 28153195
[TBL] [Abstract][Full Text] [Related]
31. Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients.
Poyrazoglu OK; Dogukan A; Yalniz M; Seckin D; Gunal AL
Ren Fail; 2006; 28(8):723-7. PubMed ID: 17162433
[TBL] [Abstract][Full Text] [Related]
32. Relationship of pregnancy-associated plasma protein-a to renal function and dialysis modalities.
Fialová L; Kalousová M; Soukupová J; Sulková S; Merta M; Jelínková E; Horejsí M; Srámek P; Malbohan I; Mikulíková L; Tesar V; Zima T
Kidney Blood Press Res; 2004; 27(2):88-95. PubMed ID: 14739577
[TBL] [Abstract][Full Text] [Related]
33. Determination of oxidative stress and cellular inflammation in patients with diabetic nephropathy and non-diabetic nephropathy being administered hemodialysis treatment due to chronic renal failure.
Avci E; Cakir E; Cevher SC; Yaman H; Agilli M; Bilgi C
Ren Fail; 2014 Jun; 36(5):767-73. PubMed ID: 24579657
[TBL] [Abstract][Full Text] [Related]
34. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study.
Nascimento MM; Suliman ME; Silva M; Chinaglia T; Marchioro J; Hayashi SY; Riella MC; Lindholm B; Anderstam B
Perit Dial Int; 2010; 30(3):336-42. PubMed ID: 20190028
[TBL] [Abstract][Full Text] [Related]
35. Oxidative stress in chronic renal failure patients treated by peritoneal dialysis.
Al-Hashimi AF; Mohammed FH; Al-Khazragi AS
Saudi Med J; 2004 Sep; 25(9):1186-92. PubMed ID: 15448763
[TBL] [Abstract][Full Text] [Related]
36. Correlation between volume overload, chronic inflammation, and left ventricular dysfunction in chronic kidney disease patients.
Hassan MO; Duarte R; Dix-Peek T; Vachiat A; Naidoo S; Dickens C; Grinter S; Manga P; Naicker S
Clin Nephrol; 2016 Supplement 1; 86 (2016)(13):131-135. PubMed ID: 27509588
[TBL] [Abstract][Full Text] [Related]
37. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease.
Barreto DV; Barreto FC; Liabeuf S; Temmar M; Lemke HD; Tribouilloy C; Choukroun G; Vanholder R; Massy ZA;
Kidney Int; 2010 Mar; 77(6):550-6. PubMed ID: 20016471
[TBL] [Abstract][Full Text] [Related]
38. Beta-glucans in advanced CKD: role in endotoxaemia and inflammation.
Wong J; Zhang Y; Swift O; Finkelman M; Patidar A; Ramanarayanan S; Vilar E; Farrington K
BMC Nephrol; 2020 Apr; 21(1):118. PubMed ID: 32252666
[TBL] [Abstract][Full Text] [Related]
39. Association of plasma adiponectin and cardiovascular risk profiles in nondiabetic uremic patients on peritoneal dialysis.
Tsao YT; Hsu YJ; Chu NF; Lai CH; Chiu JS; Lin SH
J Nephrol; 2008; 21(5):744-52. PubMed ID: 18949730
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
